focal

Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026

March 08, 2026 14:00 ET  | Source: Xenon Pharmaceuticals Inc. VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE)…

1 day ago

Continuity Biosciences Acquires Focal Medical to Advance Targeted Drug Delivery for Pancreatic Cancer

BRADENTON, Fla., June 4, 2025 /PRNewswire/ -- Continuity Biosciences, LLC, a developer of advanced drug delivery technologies, announced today the…

9 months ago